

GLAXOSMITHKLINE PLC  
Form 6-K  
January 03, 2014

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending January 2014

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No

--

Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons

I give below details of changes in the Directors' interests in the Ordinary Shares and American Depositary Shares (ADSs) of GlaxoSmithKline plc (the Company).

On 31 December 2013, the Company's Non-Executive Directors were provisionally allocated the following awards over Ordinary Shares and ADSs in the Company through the annual reinvestment of dividends paid throughout 2013; calculated using an average price of £16.07 per Ordinary Share and \$53.17 per ADS:

Non-Executive Director	Ordinary Shares	No. of ADSs
Sir Christopher Gent	4,354,409	
Prof Sir Roy Anderson	675,908	
Dr Stephanie Burns		528,928
Stacey Cartwright	125,486	
Lynn Elsenhans		62,813
Judy Lewent		80,699
Sir Deryck Maughan		1,343,402
Dr Daniel Podolsky		951,863
Tom de Swaan	980,751	
Jing Ulrich		19,485
Hans Wijers	3,631	
Sir Robert Wilson	1,485,756	

The Company and the Non-Executive Directors were informed of these allocations on 2 January 2014.

This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).

Sonja Arsenić  
Corporate Secretariat

3 January 2014

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: January 03, 2014

By: SIMON BICKNELL  
-----

Simon Bicknell  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc